2020.03.27
I-Mab Expands Global Out-Licensing and Business Development Efforts
Fernando J. Sallés, Ph.D., CLP®, Appointed to Lead I-Mab’s US and EU Business Development.
2020.03.23
I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications
I-Mab today announced the appointment of Gigi Feng as Vice President, Global Head of Corporate Communications, effective April 20th, 2020. Reporting to I-Mab’s Board of Directors, Feng will oversee all communications across I-Mab, partnering with the executive team to communicate the Company’s strat...
2020.03.13
I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)
-The clinical study will explore the potential of TJM2, a proprietary mAb against GM-CSF, to fight "cytokine storm” during severe COVID-19 disease -The study to be conducted initially in the United States with planned expansion of study into other countries.
2020.01.17
I-MAB Announces Pricing of U.S. Initial Public Offering
SHANGHAI, China & ROCKVILLE, MD., January 16, 2020 – I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical ...
2020.01.03
I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China
SHANGHAI, January 3, 2020 -- I-Mab Biopharma ("I-Mab"), a global biopharmaceutical company based in China and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced the dosing of the first ...
2019.11.14
I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China
SHANGHAI, China – November 14, 2019 – I-Mab Biopharma (“I-Mab”), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that National ...
2019.10.14
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
SHANGHAI, China – October 14, 2019 – I-Mab Biopharma (“I-Mab”), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases and German biopharma company Mo...
2019.10.04
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
SHANGHAI, China – October 4, 2019 – I-Mab Biopharma (“I-Mab”), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its IND ap...
2019.09.24
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
Shanghai, China – September 23, 2019 – I-Mab Biopharma (“I-Mab”), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, today announced ...
2019.09.12
I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S.
Shanghai and Gaithersburg, MD – September 11, 2019 – I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of innovative biologics in immuno-oncology and autoimmune diseases announced the appointment of Mr. Neil ...